MEDNAX, Inc. (NYSE: MD) and MEDNAX Radiology Solutions, one of the nation’s largest radiology practices, announced that Chief Medical Officer, Ricardo C. Cury, MD, FSCCT, will present at the 14th Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT) at the Baltimore Marriott Waterfront in Baltimore, Md. today.

Cardiologists discuss the questions and concerns swirling around the thriving wearables market as patients strap on a variety of smart devices and expect their physicians to catch up.

The Cardiovascular Research Foundation is partnering with VEITHsymposium, one of the largest annual meetings in vascular medicine, to enhance conference material at both VEITHsymposium and the CRF’s yearly Transcatheter Cardiovascular Therapeutics conference, the groups announced June 20.

Royal Philips has rolled out the latest update for its EPIQ CVx and EPIQ CVxi cardiac ultrasound systems, expanding to include automated applications for 2D assessment of the heart and robust 3D measurements of right ventricular volume and ejection fraction.

A recent analysis of the COAPT trial, published this spring in the Journal of the American College of Cardiology, suggests patients with symptomatic heart failure (HF) and secondary mitral regurgitation (MR) might see better mental and physical outcomes if they’re treated with edge-to-edge transcatheter mitral valve repair (TMVR) in lieu of standard therapy.

Corindus Vascular Robotics’ CorPath GRX system—the world’s only FDA-approved and CE-marked robotic platform for percutaneous coronary intervention (PCI) and peripheral vascular intervention—was used in the first-ever live transmission of a robotic PCI in Europe during this year's EuroPCR congress.

Cardiologist Andrea M. Russo, MD, took the reins of the Heart Rhythm Society as president this month after an induction ceremony at the organization’s annual meeting in San Francisco.

Three-year results of the BIO-RESORT study, presented at EuroPCR this week in Paris, put Biotronik’s ultrathin Orsiro stent ahead of two other competitors in terms of target lesion failure and revascularization.